Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2020

01-03-2020 | NSCLC | Original Article

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

Authors: Pazit Salamon, Yoseph A. Mekori, Irit Shefler

Published in: Cancer Immunology, Immunotherapy | Issue 3/2020

Login to get access

Abstract

Activated mast cells are often found in the tumor microenvironment. They have both pro- and anti-tumorigenic roles, depending on the tumor type. Several lines of evidence suggest that the tumor microenvironment contains multiple soluble factors that can drive mast cell recruitment and activation. However, it is not yet clear how mast cells are activated by tumor cells. In this study, we explored whether tumor-derived microvesicles (TMV) from non-small cell lung cancer (NSCLC) cells interact with human mast cells, activate them to release cytokines, and affect their migratory ability. PKH67-labelled TMV isolated from NSCLC cell lines were found to be internalized by mast cells. This internalization was first noticed after 4 h and peaked within 24 h of co-incubation. Furthermore, internalization of TMV derived from NSCLC cell lines or from surgical lung tissue specimens resulted in ERK phosphorylation, enhanced mast cell migratory ability and increased release of cytokines and chemokines, such as TNF-α and MCP-1. Our data are thus, consistent with the conclusion that TMV have the potential to influence mast cell activity and thereby, affect tumorigenesis.
Literature
4.
go back to reference Dyduch G, Kaczmarczyk K, Okon K (2012) Mast cells and cancer: enemies or allies? Pol J Pathol 63(1):1–7PubMed Dyduch G, Kaczmarczyk K, Okon K (2012) Mast cells and cancer: enemies or allies? Pol J Pathol 63(1):1–7PubMed
17.
go back to reference Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol (Baltimore, MD: 1950) 167(7):4008–4016CrossRef Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol (Baltimore, MD: 1950) 167(7):4008–4016CrossRef
21.
25.
go back to reference Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M (2006) Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother CII 55(7):808–818. https://doi.org/10.1007/s00262-005-0075-9 CrossRefPubMed Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M (2006) Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother CII 55(7):808–818. https://​doi.​org/​10.​1007/​s00262-005-0075-9 CrossRefPubMed
31.
go back to reference Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27(8):677–682CrossRef Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27(8):677–682CrossRef
Metadata
Title
Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment
Authors
Pazit Salamon
Yoseph A. Mekori
Irit Shefler
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02459-w

Other articles of this Issue 3/2020

Cancer Immunology, Immunotherapy 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine